Convalescent plasma: a valid option in the treatment of COVID-19?
Open Access
- 25 February 2020
- journal article
- Published by Heighten Science Publications Corporation in Insights in Clinical and Cellular Immunology
- Vol. 4 (1), 001-002
- https://doi.org/10.29328/journal.icci.1001012
Abstract
In the late of 2019, there is an outbreak of novel coronavirus disease (COVID-19) in Wuhan, China. The patients appear respiratory symptoms, fever, and cough, shortness of breath and breathing difficulties. In more severe cases, infection can cause pneumonia, severe acute respiratory syndrome, kidney failure and even death.Keywords
This publication has 5 references indexed in Scilit:
- Anti-influenza immune plasma for the treatment of patients with severe influenza A: a randomised, double-blind, phase 3 trialThe Lancet Respiratory Medicine, 2019
- Broad Neutralizing Activity Against Ebolaviruses Lacking the Mucin-Like Domain in Convalescent Plasma Specimens From Patients With Ebola Virus DiseaseThe Journal of Infectious Diseases, 2018
- Evaluation of Convalescent Plasma for Ebola Virus Disease in GuineaThe New England Journal of Medicine, 2016
- The Effectiveness of Convalescent Plasma and Hyperimmune Immunoglobulin for the Treatment of Severe Acute Respiratory Infections of Viral Etiology: A Systematic Review and Exploratory Meta-analysisThe Journal of Infectious Diseases, 2014
- Treatment with Convalescent Plasma for Influenza A (H5N1) InfectionThe New England Journal of Medicine, 2007